respiratori
infect
caus
wheez
ill
children
age
also
influenc
develop
sever
asthma
sever
way
first
viral
wheez
episod
infanc
critic
risk
factor
asthma
incept
asthma
establish
viral
upper
respiratori
tract
infect
urti
common
trigger
acut
exacerb
furthermor
potenti
role
particular
bacteri
pathogen
develop
wheez
asthma
exacerb
identifi
chapter
review
relationship
infect
asthma
incept
exacerb
addit
discuss
mechan
infect
lead
lower
respiratori
inflamm
airway
dysfunct
final
discuss
treatment
strategi
virusinduc
wheez
exacerb
asthma
virus
viral
respiratori
ill
lead
wheez
one
common
caus
hospit
infanc
use
multipl
viru
detect
method
includ
polymeras
chain
reaction
pcr
jartti
colleagu
investig
etiolog
wheez
ill
hospit
children
infant
viru
detect
respiratori
syncyti
viru
rsv
picornavirus
human
rhinoviru
rv
enteroviru
human
metapneumoviru
hmpv
older
children
respiratori
picornavirus
commonli
rv
domin
children
age
year
children
age
year
outpati
wheez
ill
also
extrem
common
young
children
virus
implic
episod
differ
popul
wheez
virus
infanc
often
earli
manifest
asthma
sever
larg
longterm
prospect
studi
children
demonstr
rsv
bronchiol
signific
independ
risk
factor
recurr
wheez
asthma
least
within
first
decad
life
recent
clinic
trial
compar
palivizumab
antirsv
monoclon
antibodi
placebo
near
preterm
infant
demonstr
reduct
recurr
wheez
first
year
life
children
treat
palivizumab
strongest
level
evid
date
support
causal
role
rsv
recurr
wheez
howev
longitudin
populationbas
cohort
studi
demonstr
associ
rsv
lower
respiratori
infect
earli
life
frequent
three
episod
infrequ
wheez
less
three
episod
decreas
age
becom
nonsignific
age
year
data
suggest
although
rsv
infect
contribut
substanti
risk
recurr
wheez
asthma
earli
childhood
cofactor
eg
genet
environment
development
also
contribut
express
asthma
modif
phenotyp
time
interestingli
studi
identifi
uniqu
immun
respons
profil
rsv
bronchiol
comparison
bronchiol
caus
virus
develop
molecular
diagnost
signific
evid
emerg
suggest
wheez
ill
caus
rv
identifi
children
highest
risk
childhood
asthma
childhood
origin
asthma
coast
birth
cohort
studi
confirm
prior
associ
rsv
wheez
first
year
life
childhood
asthma
demonstr
rv
wheez
time
associ
greater
increas
risk
childhood
asthma
mechan
recurr
rv
infect
may
lead
wheez
airway
remodel
particularli
suscept
host
describ
new
speci
rv
rvc
recent
discov
shown
import
caus
lower
respiratori
ill
wheez
children
longitudin
analysi
within
coast
studi
demonstr
rva
rvc
like
rvb
caus
moderatetosever
respiratori
ill
infant
whether
rvc
wheez
ill
confer
greater
risk
childhood
asthma
develop
current
unknown
molecular
diagnost
univers
avail
clinician
question
whether
season
wheez
help
diagnost
test
virus
difficult
cultur
rv
hmpv
bocavirus
advent
sensit
diagnost
tool
inform
link
common
cold
infect
exacerb
asthma
come
number
sourc
prospect
studi
children
asthma
demonstr
exacerb
wheez
asthma
children
associ
viral
infect
although
mani
respiratori
virus
provok
acut
asthma
symptom
rv
often
detect
especi
spring
fall
rv
season
fact
spring
fall
peak
hospit
asthma
close
coincid
pattern
rv
isol
within
commun
rv
infect
commonli
rvc
frequent
detect
children
present
emerg
depart
acut
wheez
children
hospit
acut
asthma
influenza
rsv
somewhat
like
trigger
acut
asthma
symptom
winter
appear
account
smaller
fraction
total
asthma
flare
virus
less
frequent
associ
wheez
exacerb
asthma
includ
bocaviru
metapneumoviru
coronavirus
togeth
studi
provid
evid
strong
relationship
viral
infect
particularli
associ
rv
acut
exacerb
asthma
interest
individu
asthma
necessarili
cold
greater
lower
respiratori
tract
symptom
associ
cold
prospect
studi
cold
coupl
consist
one
asthmat
one
healthi
individu
demonstr
cold
caus
greater
durat
sever
lower
respiratori
symptom
patient
asthma
find
suggest
asthma
associ
fundament
differ
lower
airway
manifest
respiratori
viral
infect
addit
provok
asthma
rv
infect
increas
lower
airway
obstruct
individu
chronic
airway
diseas
chronic
obstruct
pulmonari
diseas
cystic
fibrosi
thu
common
cold
virus
produc
rel
mild
ill
peopl
caus
sever
pulmonari
problem
suscept
individu
role
respiratori
virus
exacerb
particularli
import
light
recent
observ
sever
asthma
exacerb
may
lead
progress
loss
lung
function
time
seen
chronic
lung
diseas
paradigm
recurr
sever
exacerb
lead
progress
loss
lung
function
enhanc
diseas
sever
time
appear
emerg
asthma
natur
associ
asthma
sinus
children
adult
subject
debat
mani
year
much
difficulti
defin
relationship
result
uncertainti
make
clinic
diagnosi
sinus
sign
symptom
sinus
children
overlap
mani
common
childhood
respiratori
disord
includ
common
cold
allerg
rhiniti
asthma
review
chapter
untreat
sinu
diseas
may
contribut
unstabl
asthma
control
patient
bacteri
infect
clearli
involv
acut
chronic
sinu
diseas
mechan
microb
may
promot
hyperreact
lower
airway
great
interest
relationship
cover
depth
elsewher
text
therefor
review
chapter
delin
risk
import
one
bronchiol
infanc
associ
approxim
increas
risk
earli
childhood
asthma
howev
risk
differ
season
bronchiol
bronchiol
occur
rvpredomin
month
spring
fall
associ
estim
increas
risk
earli
childhood
asthma
compar
rsvpredomin
winter
month
howev
proport
associ
asthma
winter
season
bronchiol
greater
rvpredomin
month
higher
rate
bronchiol
rsv
season
season
birth
also
appear
relev
children
born
close
onset
winter
viru
season
prone
develop
lower
respiratori
tract
symptom
like
due
development
compon
relationship
time
winter
viru
peak
bacteria
propos
chronic
bacteri
infect
colon
pathogen
bacteria
could
initi
chronic
lower
airway
inflamm
impair
mucociliari
clearanc
increas
mucu
product
ultim
asthma
organ
primarili
implic
process
includ
chlamydophila
pneumonia
mycoplasma
pneumonia
streptococcu
pneu
monia
haemophilu
influenza
moraxella
catarrhali
studi
chronic
mycobacteri
chlamydophila
infect
asthma
children
yield
conflict
result
potenti
part
due
limit
current
diagnost
find
diagnost
test
upper
lower
airway
alway
concurr
diagnosi
infect
serolog
lead
inaccuraci
role
bacteria
acut
wheez
young
children
also
unclear
recent
public
suggest
pathogen
bacteria
may
play
role
acut
wheez
episod
asthma
incept
preschool
children
first
bisgaard
colleagu
found
neonat
pneumonia
h
influenza
catarrhali
combin
organ
hypopharynx
increas
risk
recurr
wheez
earli
life
diagnosi
asthma
age
year
origin
observ
made
infant
mother
asthma
research
abl
replic
find
unselect
cohort
pathogen
detect
higher
rate
preschool
children
acut
wheez
episod
interestingli
similar
predomin
proteobacteria
identifi
airway
older
children
adult
establish
asthma
furthermor
human
anim
studi
environment
exposur
protect
bacteria
appear
capac
prevent
develop
wheez
andor
asthma
young
children
studi
role
microbi
exposur
microbiom
asthma
incept
intrigu
addit
studi
high
prioriti
establish
causalityprotect
specif
observ
asthma
pathogenesi
defin
immunoinflammatori
mechan
contribut
associ
pediatr
adult
patient
relationship
viral
infect
exacerb
asthma
clarifi
develop
molecular
increas
permeabl
epithelium
may
facilit
contact
irrit
allergen
immun
cell
leav
neural
element
expos
promot
secondari
infect
bacteri
pathogen
addit
combin
epitheli
edema
slough
togeth
mucu
product
lead
airway
obstruct
wheez
review
virus
clinic
evid
rvb
speci
may
less
virul
rv
moreov
correspond
evid
vitro
studi
rvb
virus
replic
slowli
produc
less
cytopath
effect
induc
lower
interferon
inflammatori
respons
compar
rv
overal
virus
appear
attenu
virusinduc
immun
respons
necessari
clear
viral
infect
also
contribut
airway
dysfunct
symptom
caus
influx
inflammatori
cell
advers
affect
lower
airway
physiolog
antivir
immun
respons
initi
within
epitheli
cell
amplifi
resid
recruit
leukocyt
airway
virus
rv
infect
rel
cell
airway
virusinduc
inflamm
may
primari
mechan
pathogenesi
respiratori
symptom
lower
airway
dysfunct
viral
respiratori
infect
also
induc
synthesi
mani
factor
regul
airway
alveolar
develop
remodel
includ
vascular
endotheli
growth
factor
vegf
nitric
oxid
metalloproteinas
fibroblast
growth
factor
fgf
singl
repeat
bout
virusinduc
overexpress
regul
lung
develop
remodel
affect
ultim
lung
structur
function
known
could
exert
longterm
effect
lung
function
asthma
follow
viral
infect
infanc
process
associ
viral
replic
trigger
innat
immun
respons
within
epitheli
cell
viru
attach
cell
surfac
receptor
initi
immun
respons
exampl
rsv
infect
activ
signal
pathway
airway
epitheli
cell
innat
immun
system
tolllik
receptor
tlr
furthermor
develop
oxid
stress
viral
infect
activ
epitheli
cell
respons
insid
cell
viral
rna
detect
innat
immun
sensor
endosom
surfac
intracellular
protein
dsrnadepend
clinic
studi
vitro
studi
provid
number
insight
pathogenesi
virusinduc
wheez
ill
exacerb
asthma
box
respiratori
virus
rsv
influenza
well
known
infect
lower
airway
caus
bronchiti
bronchiol
pneumonia
rv
tradit
consid
upper
airway
pathogen
associ
common
cold
symptom
observ
replic
best
approxim
temperatur
upper
airway
fact
lower
airway
temperatur
conduc
rv
replic
fourthgener
bronchi
exceed
peripheri
lung
moreov
rv
type
includ
rvc
isol
replic
equal
well
rv
appear
replic
equal
well
cultur
epitheli
cell
deriv
either
upper
lower
airway
epithelium
final
rv
detect
lower
airway
cell
secret
sever
techniqu
experiment
inocul
titer
infecti
viru
lower
sputum
reach
exceed
found
nasal
secret
individu
addit
evid
experiment
infect
model
rv
frequent
detect
infant
children
lower
respiratori
sign
symptom
includ
children
hospit
pneumonia
collect
find
suggest
respiratori
virus
includ
rv
caus
wheez
ill
exacerb
asthma
mainli
infect
lower
airway
caus
amplifi
lower
airway
inflamm
first
viral
infect
damag
airway
epitheli
cell
caus
airway
edema
leakag
serum
protein
airway
effect
togeth
shed
infect
cell
airway
lead
obstruct
wheez
addit
viral
infect
stimul
mucu
secret
also
promot
format
addit
goblet
cell
mucoid
metaplasia
enhanc
mucu
secret
persist
even
acut
infect
resolv
virusinduc
injuri
epithelium
disrupt
airway
physiolog
number
differ
pathway
box
exampl
viral
infect
sever
studi
test
hypothesi
individu
variat
cellular
immun
respons
pattern
cytokin
product
relat
outcom
respiratori
infect
clinic
studi
reduc
respons
blood
mononuclear
cell
ex
vivo
associ
signific
increas
viral
respiratori
ill
infanc
addit
sever
studi
found
asthma
associ
impair
virusinduc
secret
interferon
airway
peripher
blood
cell
togeth
experiment
find
suggest
individu
variabl
cellular
immun
respons
respiratori
virus
interferon
respons
particular
influenc
clinic
virolog
outcom
infect
well
establish
viral
ill
middl
ear
sinus
lung
promot
secondari
infect
bacteri
pathogen
pneumonia
catarrhali
h
influ
enza
review
bacteria
colon
bacteria
earli
childhood
also
risk
factor
acut
wheez
episod
asthma
schoolag
children
pathogen
like
detect
associ
viral
infect
viral
infect
furthermor
risk
ill
vs
asymptomat
infect
greater
children
virus
bacteria
detect
similarli
children
asthma
moder
exacerb
like
occur
viral
infect
pneumonia
catarrhali
also
detect
find
suggest
virus
bacteria
may
work
togeth
promot
airway
patholog
respiratori
symptom
environment
factor
strongli
influenc
probabl
exacerb
appear
act
togeth
viral
infect
addit
fashion
discuss
next
section
allergi
strong
risk
factor
develop
asthma
virusinduc
wheez
episod
infanc
also
close
associ
virusinduc
exacerb
asthma
older
children
adult
asthma
accordingli
combin
allergi
exposur
relev
allergen
contribut
virusinduc
exacerb
asthma
similarli
exposur
greater
level
air
pollut
also
enhanc
risk
virusinduc
exacerb
interact
allergi
infect
allerg
sensit
defin
clear
risk
factor
develop
asthma
children
multipl
earli
sensit
aeroallergen
identifi
phenotyp
particularli
high
risk
asthma
incept
sever
exacerb
lead
hospit
sequenti
relationship
wherebi
allerg
sensit
preced
viral
wheez
notabl
rv
describ
furthermor
children
protein
kinas
pkr
retino
acidinduc
gene
rigi
activ
innat
antivir
immun
respons
pathway
viral
replic
stimul
antivir
effector
molecul
rnase
l
inhibit
protein
synthesi
within
infect
cell
addit
innat
antivir
respons
induc
chemokin
eg
recruit
inflammatori
cell
airway
type
type
iii
interferon
autocrin
paracrin
antivir
effect
respiratori
virus
activ
monocyt
macrophag
dendrit
cell
secret
array
proinflammatori
cytokin
tumor
necrosi
factor
tnf
anim
model
respiratori
viral
infect
lead
promin
expans
matur
dendrit
cell
lung
significantli
pulmonari
dendrit
cell
express
high
level
tolllik
receptor
secret
larg
amount
interferon
respons
viral
infect
dendrit
cell
interferon
respons
impair
earli
life
like
contribut
increas
suscept
viral
infect
infanc
acut
respiratori
viral
infect
often
accompani
pronounc
neutrophilia
upper
lower
respiratori
secret
product
neutrophil
activ
contribut
airway
obstruct
lower
airway
symptom
exampl
neutrophil
elastas
upregul
goblet
cell
secret
mucu
cation
channel
express
leukocyt
airway
epitheli
cell
import
pathogen
control
neutrophil
inflamm
attenu
function
common
mild
moder
asthma
associ
reduc
recruit
neutrophil
airway
rv
cold
increas
risk
acut
asthma
symptom
lymphocyt
recruit
upper
lower
airway
earli
stage
viral
respiratori
infect
presum
cell
help
limit
extent
infect
clear
virusinfect
epitheli
cell
consist
report
sever
viral
lower
respiratori
infect
immunocompromis
patient
b
cell
respons
respiratori
virus
also
serv
limit
durat
sever
ill
indic
find
frequent
prolong
viral
ill
patient
xlink
agammaglobulinemia
viral
respiratori
infect
induc
inflamm
mechan
involv
neural
mechan
respons
difficult
studi
human
studi
anim
model
provid
insight
exampl
rsv
infect
rodent
lead
overproduct
nerv
growth
factor
promot
airway
inflamm
observ
also
confirm
studi
babi
rsv
bronchiol
guinea
pig
model
viru
infect
caus
dysfunct
muscarin
receptor
parasympathet
nerv
lead
overproduct
acetylcholin
airway
hyperrespons
respons
appear
driven
virusinduc
acut
phase
cytokin
mediat
produc
excess
respiratori
ill
includ
leukotrien
prostaglandin
kinin
oxid
metabolit
inhibit
specif
mediat
amelior
cold
symptom
histamin
appear
play
role
common
cold
pathogenesi
inhal
demand
superior
inhal
fix
schedul
mani
outcom
measur
evalu
atop
background
patient
eczema
asthma
firstdegre
rel
may
influenc
respons
oral
corticosteroid
administr
infant
age
month
present
care
facil
treatment
moderatetosever
bronchiol
posit
histori
eczema
known
parent
full
sibl
prior
physician
diagnosi
asthma
treat
oral
dexamethason
mgkg
mgkg
day
match
placebo
patient
receiv
albuterol
nebul
deliv
tightfit
face
mask
pressur
oxygen
dexamethason
plu
albuterol
treatment
shorten
time
readi
discharg
unit
howev
differ
treatment
group
term
infirmari
clinic
visit
week
follow
discharg
therapeut
approach
virusinduc
wheez
preschool
children
age
year
challeng
due
fact
mani
children
wheez
common
cold
total
asymptomat
episod
other
may
symptom
less
daili
basi
well
addit
episod
may
rang
sever
mild
wheez
cough
sever
respiratori
distress
requir
prompt
medic
intervent
standard
therapi
virusinduc
wheez
young
children
gener
includ
stepwis
addit
medic
typic
commenc
bronchodil
lower
respiratori
tract
symptom
becom
increasingli
sever
respiratori
distress
develop
oral
corticosteroid
often
ad
recent
clinic
trial
manag
wheez
episod
also
includ
use
highdos
inhal
corticosteroid
prophylact
andor
acut
intervent
leukotrien
receptor
antagonist
numer
studi
undertaken
assess
role
corticosteroid
therapi
acut
episod
asthma
children
adult
metaanalys
studi
support
earli
use
system
corticosteroid
acut
exacerb
base
upon
reduct
admiss
rate
asthma
prevent
relaps
outpati
treatment
exacerb
reflect
inform
recent
nation
heart
lung
blood
institut
nhlbi
guidelin
diagnosi
manag
asthma
recommend
addit
corticosteroid
asthma
exacerb
unrespons
bronchodil
contrast
previou
version
guidelin
doubl
dose
inhal
corticosteroid
prevent
progress
airway
obstruct
recommend
unfortun
applic
recommend
young
children
infant
whose
acut
wheez
episod
primarili
relat
viral
respiratori
tract
infect
thoroughli
examin
moreov
studi
conduct
age
group
result
conflict
limit
studi
includ
inclus
multipl
develop
risk
factor
earli
life
highest
risk
subsequ
asthma
convinc
evid
implic
respiratori
allergi
risk
factor
wheez
common
cold
infect
later
childhood
studi
conduct
emerg
depart
risk
factor
develop
acut
wheez
episod
determin
individu
risk
factor
develop
wheez
includ
detect
respiratori
viru
commonli
rv
posit
allergenspecif
ige
presenc
eosinophil
inflamm
notabl
viral
infect
allerg
inflamm
synergist
enhanc
risk
wheez
higher
level
allergenspecif
ige
confer
greatest
risk
synerg
may
particularli
notabl
rvc
multipl
mechan
viral
infect
thought
interact
allerg
inflamm
order
lead
airway
dysfunct
wheez
asthma
exacerb
first
viral
infect
damag
barrier
function
airway
epithelium
lead
enhanc
absorpt
aeroallergen
across
airway
wall
enhanc
inflamm
allerg
inflamm
may
also
lead
enhanc
viral
replic
next
allerg
inflamm
enhanc
airway
respons
rv
also
signific
evid
allerg
asthmat
individu
impair
antivir
respons
note
furthermor
allergen
exposur
highaffin
ige
receptor
crosslink
shown
impair
virusinduc
type
iii
interferon
product
peripher
blood
cell
may
lead
enhanc
viral
replic
also
type
inflamm
acut
lower
respiratori
tract
ill
first
one
two
year
life
usual
term
bronchiol
like
due
infect
viral
respiratori
pathogen
efficaci
variou
intervent
treatment
acut
lower
airway
symptom
wheez
tachypnea
retract
hypoxemia
occur
result
infect
controversi
due
variat
studi
design
inabl
rapidli
conveni
measur
pulmonari
physiolog
variabl
confound
result
inclus
children
histori
multipl
wheez
episod
ie
asthmat
phenotyp
choic
outcom
measur
evalu
recent
seri
metaanalys
evalu
variou
therapi
routin
use
bronchodil
steam
nebul
normal
salin
anticholinerg
steroid
shown
consist
benefit
recent
studi
suggest
time
administr
epinephrin
may
influenc
observ
benefit
eightcent
random
doubleblind
trial
twobytwo
factori
design
investig
compar
inhal
racem
epinephrin
inhal
salin
ondemand
inhal
fixedschedul
inhal
everi
hour
infant
month
age
moderatetosever
acut
bronchiol
length
stay
use
oxygen
supplement
nasogastr
tube
feed
ventilatori
support
rel
improv
clinic
score
baselin
preinhal
similar
infant
treat
inhal
racem
epinephrin
treat
inhal
salin
howev
strategi
signific
reduct
oral
corticosteroidrequir
exacerb
reduct
less
use
prespecifi
stepup
plan
pulmonari
function
also
significantli
better
end
treatment
period
children
receiv
ic
previou
two
year
unfortun
three
month
observ
period
longer
signific
differ
outcom
measur
end
observ
period
year
later
pulmonari
function
also
differ
two
group
data
indic
continu
therapi
ic
preschool
children
high
risk
develop
asthma
reduc
lower
respiratori
tract
exacerb
frequent
caus
respiratori
pathogen
age
group
mani
preschool
children
wheez
respiratori
tract
pathogen
asymptomat
episod
therefor
random
doubleblind
comparison
among
intermitt
treatment
highdos
ic
leukotrien
receptor
antagonist
montelukast
schedul
albuterol
socal
standard
care
conduct
preschool
children
histori
consist
type
respiratori
pattern
therapi
initi
famili
base
particip
achiev
symptom
profil
threshold
child
exhibit
past
would
usual
foreshadow
develop
signific
lower
airway
involv
year
treatment
three
group
differ
proport
episodefre
day
primari
outcom
oral
corticosteroid
use
healthcar
util
qualiti
life
linear
growth
howev
respiratori
tract
ill
ic
montelukast
therapi
led
modest
reduct
troubl
breath
interfer
activ
score
compar
children
treat
albuterol
differ
signific
children
posit
asthma
predict
index
prior
enrol
post
hoc
analysi
similar
find
obtain
cohort
stratifi
oral
corticosteroid
use
vs
cours
year
preced
particip
trial
observ
continu
intermitt
use
ic
effect
frequenc
sever
exacerb
like
relat
concomit
viral
bacteri
respiratori
tract
ill
provid
impetu
third
care
networkiniti
trial
trial
studi
children
age
month
posit
modifi
asthma
predict
indic
recurr
wheez
episod
low
grade
interv
impair
least
one
exacerb
previou
year
children
randomli
assign
receiv
nebul
budesonid
suspens
year
either
intermitt
highdos
regimen
mg
twice
daili
day
start
onset
predefin
respiratori
tract
ill
symptom
daili
lowdos
regimen
mg
nightli
correspond
placebo
treatment
arm
two
regimen
similar
respect
exacerb
frequenc
primari
outcom
measur
asthma
sever
includ
time
first
exacerb
mean
exposur
budesonid
mg
less
intermitt
regimen
although
result
trial
indic
preschool
children
type
preasthma
phenotyp
intermitt
therapi
versu
continu
therapi
would
therapeut
consider
lack
placebo
group
studi
permit
exact
interpret
find
inclus
placebo
group
permit
variou
human
subject
committe
clinic
center
particip
wheez
phenotyp
rel
small
sampl
size
poor
adher
studi
medic
protocol
outpati
studi
episod
rel
mild
sever
outpati
inpati
studi
recent
random
doubleblind
placebocontrol
trial
compar
cours
oral
prednisolon
mg
day
children
month
age
mg
day
older
children
total
day
placebo
children
age
month
month
primari
outcom
durat
hospit
differ
treatment
group
accompani
editori
publish
studi
challeng
clinic
research
commun
conduct
addit
prospect
trial
clearli
establish
efficaci
oral
corticosteroid
treatment
asthmalik
episod
preschool
children
address
concern
childhood
asthma
research
educ
care
network
investig
whether
oral
corticosteroid
reduc
symptom
score
acut
lower
respiratori
tract
ill
lrti
preschool
children
recurr
wheez
investig
perform
post
hoc
replic
analys
two
outpati
cohort
children
age
year
episod
wheez
particip
previou
careconduct
studi
comparison
made
symptom
score
lrti
treat
oral
corticosteroid
adjust
differ
diseas
episod
sever
primari
outcom
area
curv
total
symptom
score
among
sever
episod
two
cohort
studi
independ
oral
corticosteroid
treatment
reduc
symptom
sever
acut
lrti
moreov
subgroup
children
might
like
experi
benefit
asthma
risk
factor
posit
modifi
asthma
predict
index
person
eczema
andor
famili
histori
asthma
appear
greater
benefit
without
characterist
investig
emphas
howev
result
hypothesi
gener
need
confirm
random
prospect
studi
taken
togeth
howev
studi
indic
acut
asthmalik
episod
airway
obstruct
preschool
children
appear
respond
less
well
oral
corticosteroid
administr
similar
episod
older
children
adult
care
network
conduct
prospect
trial
preschool
children
modifi
posit
asthma
predict
index
overal
goal
studi
determin
earli
recognit
treatment
children
increas
risk
develop
childhood
asthma
could
prevent
diseas
process
express
could
reduc
loss
lung
function
describ
first
six
year
life
children
develop
persist
wheez
age
year
children
year
age
random
receiv
either
fluticason
propion
twice
daili
match
placebo
use
valv
spacer
mask
treatment
year
follow
observ
period
studi
medic
primari
outcom
measur
episodefre
day
activ
treatment
phase
children
receiv
inhal
corticosteroid
ic
significantli
increas
number
episodefre
day
addit
season
variat
exacerb
rate
summer
month
less
frequent
exacerb
observ
treatment
effect
data
excel
document
honeymoon
period
asthma
symptom
mani
clinician
observ
patient
summer
month
like
relat
reduc
number
respiratori
tract
ill
infect
rsv
earli
life
associ
increas
risk
develop
recurr
wheez
later
asthma
two
studi
evalu
effect
montelukast
treatment
develop
subsequ
reactiv
airway
diseas
symptom
first
pilot
studi
children
without
diagnosi
asthma
month
old
hospit
acut
rsv
bronchiol
random
doubleblind
parallel
comparison
mg
montelukast
placebo
given
day
start
within
day
onset
symptom
infant
montelukast
free
symptom
day
night
compar
day
night
infant
placebo
daytim
cough
significantli
reduc
exacerb
children
activ
treatment
contrast
followup
studi
children
month
age
conduct
period
week
montelukast
treatment
allevi
post
rsvinduc
respiratori
tract
symptom
schoolag
children
montelukast
shown
less
effect
compar
inhal
corticosteroid
treatment
reduc
need
oral
corticosteroid
use
time
treatment
failur
time
period
outcom
could
consid
surrog
respiratori
pathogeninduc
asthma
exacerb
worsen
overal
asthma
control
therapi
infectioninduc
asthma
could
potenti
includ
one
follow
approach
avoid
nonmedicin
intervent
vaccin
antimicrobi
drug
therapi
andor
immunotherapi
monoclon
antibodi
direct
relev
pathogen
ubiquit
natur
respiratori
pathogen
environ
social
natur
interact
childhood
daycar
school
older
sibl
etc
make
avoid
strategi
unfeas
inde
averag
children
experi
cold
per
year
preschool
year
cure
common
cold
remain
elus
number
nonmedicin
intervent
tri
vitamin
c
long
tout
common
cold
treatment
howev
metaanalysi
common
cold
treatment
studi
found
signific
effect
either
prevent
treatment
cochran
review
clinic
studi
found
evid
zinc
lozeng
reduc
common
cold
durat
signific
sideeffect
includ
bad
tast
nausea
largescal
trial
echinacea
provid
evid
efficaci
evid
warm
drink
recommend
gener
provid
symptomat
relief
malais
nasal
symptom
without
troublesom
sideeffect
approach
obvious
aim
symptom
reduct
common
cold
effect
asthma
control
exacerb
directli
evalu
given
close
relationship
viral
infect
wheez
ill
children
would
attract
appli
antivir
strategi
prevent
treatment
asthma
trial
due
intens
symptom
sever
pattern
present
children
prior
enrol
trial
cysteinyl
leukotrien
identifi
import
mediat
complex
pathophysiolog
asthma
leukotrien
detect
blood
urin
nasal
secret
sputum
bronchoalveolar
lavag
fluid
patient
chronic
asthma
addit
leukotrien
releas
acut
asthma
episod
result
potenti
mediat
influenc
airway
tone
inflammatori
cascad
mucu
secret
antagonist
receptor
develop
extens
studi
cysteinyl
leukotrien
receptor
antagonist
montelukast
frequent
studi
preschool
schoolag
children
one
initi
clinic
trial
design
primarili
evalu
safeti
patient
age
year
treat
week
montelukast
administ
chewabl
tablet
efficaci
outcom
also
evalu
secondarili
compar
placebo
montelukast
produc
signific
improv
multipl
paramet
asthma
control
includ
daytim
asthma
symptom
cough
wheez
troubl
breath
activ
limit
overnight
asthma
symptom
cough
percentag
day
asthma
symptom
percentag
day
without
asthma
need
betaagonist
oral
corticosteroid
physician
global
evalu
peripher
blood
eosinophil
clinic
benefit
montelukast
evid
within
day
start
therapi
improv
asthma
control
consist
across
age
sex
race
studi
center
whether
patient
posit
vitro
allergenspecif
ige
test
robertson
et
al
evalu
intermitt
use
montelukast
children
histori
intermitt
asthma
famili
instruct
begin
treatment
montelukast
ageappropri
dose
onset
asthma
symptom
first
sign
upper
respiratori
tract
ill
previous
associ
subsequ
develop
lower
airway
asthma
symptom
compar
placebo
montelukast
treatment
result
modest
reduct
acut
healthcar
resourc
util
symptom
time
school
parent
time
work
children
intermitt
asthma
bisgaard
et
al
evalu
efficaci
daili
treatment
montelukast
children
intermitt
asthma
reduc
exacerb
primari
efficaci
endpoint
number
asthma
exacerb
episod
defin
three
consecut
day
daytim
symptom
averag
score
four
daili
daytim
symptom
question
least
day
least
two
treatment
betaagonist
per
day
rescu
use
oralinh
corticosteroid
day
hospit
asthma
month
therapi
montelukast
significantli
reduc
rate
asthma
exacerb
compar
placebo
averag
rate
exacerb
episod
per
patient
episod
per
year
montelukast
compar
episod
placebo
montelukast
also
delay
median
time
first
exacerb
approxim
month
rate
inhal
corticosteroid
cours
compar
placebo
unfortun
treatment
reduc
necess
oral
corticosteroid
administr
one
remark
aspect
trial
mark
narrowli
focuss
intervent
type
hypersensit
placebocontrol
trial
guidelinesbas
asthma
treatment
compar
omalizumab
ad
standard
therapi
omalizumab
prevent
season
increas
exacerb
fall
spring
peak
time
viral
exacerb
figur
analysi
virus
nasal
secret
subset
exacerb
confirm
treatment
group
fewer
viral
nonvir
exacerb
studi
provid
direct
evid
igemedi
inflamm
contribut
risk
virusinduc
exacerb
asthma
observ
indic
interact
allerg
sensit
antigenspecif
ige
antibodi
format
viral
respiratori
ill
play
import
role
asthma
control
final
interest
determin
whether
drug
target
specif
cytokin
eg
mepolizumab
also
reduc
risk
virusinduc
exacerb
asthma
guidelin
usa
http
wwwnhlbinihgov
healthproguidelinescurrentasthmaguidelinesfullreporthtm
intern
http
wwwginasthmaorg
recommend
use
antibiot
treat
asthma
exacerb
major
exacerb
consid
trigger
viral
respiratori
tract
infect
nonetheless
oral
antibiot
frequent
prescrib
wheez
ill
preschool
children
antibiot
wheez
children
furthermor
recent
data
indic
preschool
children
make
physician
visit
wheez
receiv
prescript
antibiot
within
day
visit
receiv
prescript
antibiot
within
day
prescript
domin
azithromycin
use
increas
note
previous
bacteria
either
alon
combin
viral
pathogen
demonstr
potenti
play
role
acut
wheez
episod
increas
asthma
symptom
children
observ
might
explan
antibiot
administr
observ
provid
clinic
benefit
practition
recent
find
indic
certain
antimicrobi
may
rv
rsv
obviou
target
attempt
develop
rsv
vaccin
far
unsuccess
howev
recent
data
provid
renew
encourag
unfortun
vaccin
prevent
rv
infect
even
challeng
due
larg
number
serotyp
altern
sever
type
antivir
agent
develop
sever
compound
activ
rv
test
clinic
trial
improv
knowledg
rv
molecular
virolog
led
sever
attempt
develop
antivir
agent
antivir
effect
vitro
shorten
durat
sever
cold
topic
applic
led
nasal
irrit
bleed
solubl
develop
prevent
bind
major
group
virus
receptor
capsid
bind
agent
bind
pocket
inhibit
viral
bind
andor
uncoat
shown
modest
antivir
effect
efficaci
clinic
trial
inhibitor
proteas
rupintrivir
also
show
broad
antihrv
activ
vitro
efficaci
clinic
trial
unfortun
antivir
approach
far
led
develop
clinic
use
medic
molecul
test
date
limit
combin
modest
efficaci
sideeffect
andor
drug
interact
anoth
new
approach
boost
antivir
defens
lung
inhal
random
studi
subject
persist
asthma
histori
exacerb
cold
treat
either
nebul
placebo
within
hour
onset
cold
symptom
intenttotreat
popul
signific
effect
asthma
symptom
score
primari
outcom
treatment
improv
recoveri
peak
expiratori
flow
notabl
well
toler
also
induc
express
innat
antivir
effector
blood
sputum
subgroup
analysi
studi
subject
sever
asthma
british
thorac
societi
step
cold
associ
increas
symptom
placebo
group
subject
excit
new
find
confirm
suggest
inhal
use
first
sign
cold
could
use
adjunct
standard
therapi
patient
sever
asthma
two
recent
trial
evalu
efficaci
monoclon
antibodi
therapi
direct
specif
rsv
allerg
antibodi
ige
yield
interest
result
first
trial
studi
antirsv
monoclon
antibodi
palivizumab
doubleblind
placebocontrol
trial
otherwis
healthi
preterm
week
gestat
age
infant
randomli
assign
receiv
either
monthli
palivizumab
inject
placebo
rsv
season
prespecifi
primari
outcom
total
number
parentreport
wheez
day
first
year
life
nasopharyng
swab
taken
respiratori
episod
viral
analysi
palivizumab
treatment
result
rel
reduct
total
number
wheez
day
first
year
life
vs
placebo
group
time
proport
infant
recurr
wheez
percentag
point
lower
patient
treat
palivizumab
vs
discuss
data
gener
thu
far
ascertain
effect
treatment
may
subsequ
develop
asthma
later
childhood
second
trial
evalu
antiig
monoclon
antibodi
omalizumab
specif
target
fc
portion
ige
prevent
bind
surfac
cell
therefor
clarithromycin
week
benefici
improv
lung
function
patient
posit
pcr
find
mycoplasma
pneumonia
c
pneumonia
initi
intrigu
result
later
expand
upon
asthma
clinic
research
network
treat
asthma
patient
adequ
control
inhal
corticosteroid
monotherapi
clarithromycin
placebo
week
found
treatment
intervent
improv
asthma
control
although
improv
airway
hyperrespons
clarithromycin
benefit
accompani
improv
secondari
outcom
one
addit
studi
suggest
benefit
might
possibl
follow
intervent
antimicrobi
class
johnston
et
al
administ
ketolid
telithromycin
semisynthet
deriv
erythromycin
day
adult
asthma
seen
within
first
hour
acut
asthma
episod
intervent
result
signific
improv
symptom
score
lung
function
next
day
rel
placebo
howev
relationship
bacteriolog
statu
respons
telithromycin
treatment
suggest
mechan
action
unrel
antimicrobi
properti
telithromycin
infect
play
critic
role
incept
exacerb
asthma
viral
infect
common
caus
wheez
infant
children
interact
underli
allergi
viru
infect
lead
greatest
risk
asthma
incept
exacerb
new
data
indic
airway
microbiom
may
play
critic
role
modul
respons
respiratori
viral
infect
virusinduc
alter
airway
microbi
popul
like
also
contribut
ill
sever
treatment
virusinduc
wheez
asthma
exacerb
remain
challeng
novel
therapi
approach
prevent
asthma
asthma
exacerb
need
complet
refer
list
found
companion
expert
consult
websit
http
wwwexpertconsultinkl
com
antibacteri
properti
antivir
andor
antiinflammatori
properti
well
class
macrolid
demonstr
provid
clinic
benefit
airway
diseas
cystic
fibrosi
diffus
panbronchiol
possibl
mechan
unrel
antimicrobi
activ
viral
infect
particularli
caus
rv
associ
neutrophil
inflamm
increas
express
neutrophil
predomin
inflammatori
cell
onset
infect
includ
rv
although
mani
chemoattract
particip
summon
neutrophil
site
infect
seem
play
central
role
neutrophil
rel
insensit
therapeut
effect
corticosteroid
interestingli
azithromycin
demonstr
attenu
immunoinflammatori
respons
may
reduc
ensu
destruct
neutrophil
inflamm
addit
recent
data
demonstr
azithromycin
reduc
rv
replic
increas
interferon
gene
express
human
bronchial
epitheli
cell
effect
may
substanti
clinic
relev
recent
studi
demonstr
primari
bronchial
epitheli
cell
asthmat
defici
ex
vivo
induct
infect
rv
level
invers
relat
sever
rvinduc
asthma
exacerb
term
declin
fev
viral
load
find
especi
import
children
viral
infect
shown
mani
investig
major
etiolog
agent
episod
clinic
signific
lower
respiratori
tract
symptom
contrast
vitro
observ
indic
potenti
use
role
agent
treat
infectioninduc
loss
asthma
control
exacerb
efficaci
human
consist
shown
black
et
al
one
first
group
demonstr
potenti
benefici
effect
studi
effect
roxithromycin
subject
asthma
immunoglobulin
g
igg
iga
antibodi
chlamydophila
pneu
monia
subject
random
week
treatment
roxithromycin
placebo
intervent
led
improv
asthma
control
benefit
sustain
kraft
colleagu
perform
addit
studi
use
differ
antimicrobi
found
treatment
